Table 1 Open in new tab Baseline...

	Overall	electronic Frailty Index Category
N	4670	1865	1699	798	308
Patient demographics
Age (years)	77 [71–84]	72 [68–78]	79 [72–85]	81 [75–86]	82 [78–88]	<.001
Female	2014 (43%)	645 (35%)	784 (46%)	406 (51%)	179 (58%)	<.001
White	3865 (83%)	1419 (76%)	1449 (85%)	707 (89%)	290 (94%)	<.001
Deprivation (SIMD 1^st quintile)	648 (14%)	204 (11%)	235 (14%)	148 (19%)	61 (20%)	<.001
Chest pain as presenting symptom	3680 (82%)	1567 (87%)	1326 (81%)	568 (74%)	219 (73%)	<.001
Past medical history
Ischaemic heart disease	1989 (43%)	418 (22%)	805 (47%)	522 (65%)	244 (79%)	<.001
Myocardial infarction	1061 (23%)	213 (11%)	434 (26%)	287 (36%)	127 (41%)	<.001
Heart failure	772 (17%)	68 (3.6%)	274 (16%)	288 (36%)	142 (46%)	<.001
Cerebrovascular disease	838 (18%)	98 (5.3%)	323 (19%)	277 (35%)	140 (45%)	<.001
Peripheral vascular disease	558 (12%)	73 (3.9%)	227 (13%)	173 (22%)	85 (28%)	<.001
Diabetes mellitus	1139 (24%)	206 (11%)	446 (26%)	325 (41%)	162 (53%)	<.001
Chronic kidney disease	1249 (27%)	286 (15%)	494 (29%)	331 (41%)	138 (45%)	<.001
Hypertension	2964 (63%)	930 (50%)	1029 (61%)	497 (62%)	187 (61%)	<.001
Dementia	344 (7%)	40 (2%)	130 (7.7%)	115 (14%)	59 (19%)	<.001
Charlson comorbidity index >2	743 (16%)	65 (3%)	254 (15%)	282 (35%)	142 (46%)	<.001
Haematology and clinical chemistry
Haemoglobin, g/L	132 [118–145]	139 [127–150]	129 [116–143]	124 [110–136]	119 [106–131]	<.001
Estimated glomerular filtration rate, mL/min¶	70 [49–84]	77 [65–89]	68 [47–82]	53 [36–72]	48 [32–70]	<.001
Peak high sensitivity troponin I, ng/L (log)
NSTEMI	7.02 [5.24–8.63]	7.10 [5.27–8.66]	7.06 [5.32–8.67]	6.92 [5.23–8.61]	6.35 [4.66–8.18]	.02
STEMI	9.86 [8.22–10.82]	9.96 [8.35–10.82]	9.85 [8.18–10.82]	9.45 [7.94–10.82]	9.71 [7.98–10.82]	.08
Clinical diagnosis
NSTEMI	3262 (70%)	1075 (58%)	1264 (74%)	656 (82%)	267 (87%)	<.001
STEMI	1408 (30%)	790 (42%)	435 (26%)	142 (18%)	41 (13%)
Primary treating speciality
Cardiology	3146 (67%)	1586 (85%)	1097 (65%)	364 (46%)	99 (32%)	<.001
Medical therapy*
Aspirin	2587 (65%)	1292 (76%)	837 (59%)	340 (54%)	118 (52%)	<.001
P2Y12 inhibitor	3020 (75%)	1411 (83%)	1044 (73%)	420 (66%)	145 (63%)	<.001
Dual antiplatelet therapy†	2318 (58%)	1208 (71%)	736 (52%)	281 (44%)	93 (41%)	<.001
Anticoagulation‡	340 (9%)	90 (5.3%)	136 (9.5%)	83 (13%)	31 (14%)	<.001
ACE inhibitor or ARB	2067 (52%)	1061 (63%)	695 (49%)	248 (39%)	63 (28%)	<.001
Beta-blocker	2065 (52%)	1013 (60%)	677 (47%)	294 (47%)	81 (35%)	<.001
Lipid lowering therapy	2544 (64%)	1305 (77%)	837 (59%)	303 (48%)	99 (43%)	<.001
Revascularisation
Coronary angiography	2654 (57%)	1452 (78%)	881 (52%)	265 (33%)	56 (18%)	<.001
Percutaneous coronary intervention	1993 (43%)	1138 (61%)	622 (37%)	195 (24%)	38 (12%)	<.001
Coronary artery bypass grafting	151 (3%)	86 (5%)	46 (3%)	15 (2%)	<5	<.001

Overall

electronic Frailty Index Category

Fit

Mild

Moderate

Severe

P-value

4670

1865

1699

798

308

Patient demographics

Age (years)

77 [71–84]

72 [68–78]

79 [72–85]

81 [75–86]

82 [78–88]

<.001

Female

2014 (43%)

645 (35%)

784 (46%)

406 (51%)

179 (58%)

<.001

White

3865 (83%)

1419 (76%)

1449 (85%)

707 (89%)

290 (94%)

<.001

Deprivation (SIMD 1^st quintile)

648 (14%)

204 (11%)

235 (14%)

148 (19%)

61 (20%)

<.001

Chest pain as presenting symptom

3680 (82%)

1567 (87%)

1326 (81%)

568 (74%)

219 (73%)

<.001

Past medical history

Ischaemic heart disease

1989 (43%)

418 (22%)

805 (47%)

522 (65%)

244 (79%)

<.001

Myocardial infarction

1061 (23%)

213 (11%)

434 (26%)

287 (36%)

127 (41%)

<.001

Heart failure

772 (17%)

68 (3.6%)

274 (16%)

288 (36%)

142 (46%)

<.001

Cerebrovascular disease

838 (18%)

98 (5.3%)

323 (19%)

277 (35%)

140 (45%)

<.001

Peripheral vascular disease

558 (12%)

73 (3.9%)

227 (13%)

173 (22%)

85 (28%)

<.001

Diabetes mellitus

1139 (24%)

206 (11%)

446 (26%)

325 (41%)

162 (53%)

<.001

Chronic kidney disease

1249 (27%)

286 (15%)

494 (29%)

331 (41%)

138 (45%)

<.001

Hypertension

2964 (63%)

930 (50%)

1029 (61%)

497 (62%)

187 (61%)

<.001

Dementia

344 (7%)

40 (2%)

130 (7.7%)

115 (14%)

59 (19%)

<.001

Charlson comorbidity index >2

743 (16%)

65 (3%)

254 (15%)

282 (35%)

142 (46%)

<.001

Haematology and clinical chemistry

Haemoglobin, g/L

132 [118–145]

139 [127–150]

129 [116–143]

124 [110–136]

119 [106–131]

<.001

Estimated glomerular filtration rate, mL/min¶

70 [49–84]

77 [65–89]

68 [47–82]

53 [36–72]

48 [32–70]

<.001

Peak high sensitivity troponin I, ng/L (log)

NSTEMI

7.02 [5.24–8.63]

7.10 [5.27–8.66]

7.06 [5.32–8.67]

6.92 [5.23–8.61]

6.35 [4.66–8.18]

.02

STEMI

9.86 [8.22–10.82]

9.96 [8.35–10.82]

9.85 [8.18–10.82]

9.45 [7.94–10.82]

9.71 [7.98–10.82]

.08

Clinical diagnosis

NSTEMI

3262 (70%)

1075 (58%)

1264 (74%)

656 (82%)

267 (87%)

<.001

STEMI

1408 (30%)

790 (42%)

435 (26%)

142 (18%)

41 (13%)

Primary treating speciality

Cardiology

3146 (67%)

1586 (85%)

1097 (65%)

364 (46%)

99 (32%)

<.001

Medical therapy*

Aspirin

2587 (65%)

1292 (76%)

837 (59%)

340 (54%)

118 (52%)

<.001

P2Y12 inhibitor

3020 (75%)

1411 (83%)

1044 (73%)

420 (66%)

145 (63%)

<.001

Dual antiplatelet therapy†

2318 (58%)

1208 (71%)

736 (52%)

281 (44%)

93 (41%)

<.001

Anticoagulation‡

340 (9%)

90 (5.3%)

136 (9.5%)

83 (13%)

31 (14%)

<.001

ACE inhibitor or ARB

2067 (52%)

1061 (63%)

695 (49%)

248 (39%)

63 (28%)

<.001

Beta-blocker

2065 (52%)

1013 (60%)

677 (47%)

294 (47%)

81 (35%)

<.001

Lipid lowering therapy

2544 (64%)

1305 (77%)

837 (59%)

303 (48%)

99 (43%)

<.001

Revascularisation

Coronary angiography

2654 (57%)

1452 (78%)

881 (52%)

265 (33%)

56 (18%)

<.001

Percutaneous coronary intervention

1993 (43%)

1138 (61%)

622 (37%)

195 (24%)

38 (12%)

<.001

Coronary artery bypass grafting

151 (3%)

86 (5%)

46 (3%)

15 (2%)

<.001

	Overall	electronic Frailty Index Category
N	4670	1865	1699	798	308
Patient demographics
Age (years)	77 [71–84]	72 [68–78]	79 [72–85]	81 [75–86]	82 [78–88]	<.001
Female	2014 (43%)	645 (35%)	784 (46%)	406 (51%)	179 (58%)	<.001
White	3865 (83%)	1419 (76%)	1449 (85%)	707 (89%)	290 (94%)	<.001
Deprivation (SIMD 1^st quintile)	648 (14%)	204 (11%)	235 (14%)	148 (19%)	61 (20%)	<.001
Chest pain as presenting symptom	3680 (82%)	1567 (87%)	1326 (81%)	568 (74%)	219 (73%)	<.001
Past medical history
Ischaemic heart disease	1989 (43%)	418 (22%)	805 (47%)	522 (65%)	244 (79%)	<.001
Myocardial infarction	1061 (23%)	213 (11%)	434 (26%)	287 (36%)	127 (41%)	<.001
Heart failure	772 (17%)	68 (3.6%)	274 (16%)	288 (36%)	142 (46%)	<.001
Cerebrovascular disease	838 (18%)	98 (5.3%)	323 (19%)	277 (35%)	140 (45%)	<.001
Peripheral vascular disease	558 (12%)	73 (3.9%)	227 (13%)	173 (22%)	85 (28%)	<.001
Diabetes mellitus	1139 (24%)	206 (11%)	446 (26%)	325 (41%)	162 (53%)	<.001
Chronic kidney disease	1249 (27%)	286 (15%)	494 (29%)	331 (41%)	138 (45%)	<.001
Hypertension	2964 (63%)	930 (50%)	1029 (61%)	497 (62%)	187 (61%)	<.001
Dementia	344 (7%)	40 (2%)	130 (7.7%)	115 (14%)	59 (19%)	<.001
Charlson comorbidity index >2	743 (16%)	65 (3%)	254 (15%)	282 (35%)	142 (46%)	<.001
Haematology and clinical chemistry
Haemoglobin, g/L	132 [118–145]	139 [127–150]	129 [116–143]	124 [110–136]	119 [106–131]	<.001
Estimated glomerular filtration rate, mL/min¶	70 [49–84]	77 [65–89]	68 [47–82]	53 [36–72]	48 [32–70]	<.001
Peak high sensitivity troponin I, ng/L (log)
NSTEMI	7.02 [5.24–8.63]	7.10 [5.27–8.66]	7.06 [5.32–8.67]	6.92 [5.23–8.61]	6.35 [4.66–8.18]	.02
STEMI	9.86 [8.22–10.82]	9.96 [8.35–10.82]	9.85 [8.18–10.82]	9.45 [7.94–10.82]	9.71 [7.98–10.82]	.08
Clinical diagnosis
NSTEMI	3262 (70%)	1075 (58%)	1264 (74%)	656 (82%)	267 (87%)	<.001
STEMI	1408 (30%)	790 (42%)	435 (26%)	142 (18%)	41 (13%)
Primary treating speciality
Cardiology	3146 (67%)	1586 (85%)	1097 (65%)	364 (46%)	99 (32%)	<.001
Medical therapy*
Aspirin	2587 (65%)	1292 (76%)	837 (59%)	340 (54%)	118 (52%)	<.001
P2Y12 inhibitor	3020 (75%)	1411 (83%)	1044 (73%)	420 (66%)	145 (63%)	<.001
Dual antiplatelet therapy†	2318 (58%)	1208 (71%)	736 (52%)	281 (44%)	93 (41%)	<.001
Anticoagulation‡	340 (9%)	90 (5.3%)	136 (9.5%)	83 (13%)	31 (14%)	<.001
ACE inhibitor or ARB	2067 (52%)	1061 (63%)	695 (49%)	248 (39%)	63 (28%)	<.001
Beta-blocker	2065 (52%)	1013 (60%)	677 (47%)	294 (47%)	81 (35%)	<.001
Lipid lowering therapy	2544 (64%)	1305 (77%)	837 (59%)	303 (48%)	99 (43%)	<.001
Revascularisation
Coronary angiography	2654 (57%)	1452 (78%)	881 (52%)	265 (33%)	56 (18%)	<.001
Percutaneous coronary intervention	1993 (43%)	1138 (61%)	622 (37%)	195 (24%)	38 (12%)	<.001
Coronary artery bypass grafting	151 (3%)	86 (5%)	46 (3%)	15 (2%)	<5	<.001

Overall

electronic Frailty Index Category

Fit

Mild

Moderate

Severe

P-value

4670

1865

1699

798

308

Patient demographics

Age (years)

77 [71–84]

72 [68–78]

79 [72–85]

81 [75–86]

82 [78–88]

<.001

Female

2014 (43%)

645 (35%)

784 (46%)

406 (51%)

179 (58%)

<.001

White

3865 (83%)

1419 (76%)

1449 (85%)

707 (89%)

290 (94%)

<.001

Deprivation (SIMD 1^st quintile)

648 (14%)

204 (11%)

235 (14%)

148 (19%)

61 (20%)

<.001

Chest pain as presenting symptom

3680 (82%)

1567 (87%)

1326 (81%)

568 (74%)

219 (73%)

<.001

Past medical history

Ischaemic heart disease

1989 (43%)

418 (22%)

805 (47%)

522 (65%)

244 (79%)

<.001

Myocardial infarction

1061 (23%)

213 (11%)

434 (26%)

287 (36%)

127 (41%)

<.001

Heart failure

772 (17%)

68 (3.6%)

274 (16%)

288 (36%)

142 (46%)

<.001

Cerebrovascular disease

838 (18%)

98 (5.3%)

323 (19%)

277 (35%)

140 (45%)

<.001

Peripheral vascular disease

558 (12%)

73 (3.9%)

227 (13%)

173 (22%)

85 (28%)

<.001

Diabetes mellitus

1139 (24%)

206 (11%)

446 (26%)

325 (41%)

162 (53%)

<.001

Chronic kidney disease

1249 (27%)

286 (15%)

494 (29%)

331 (41%)

138 (45%)

<.001

Hypertension

2964 (63%)

930 (50%)

1029 (61%)

497 (62%)

187 (61%)

<.001

Dementia

344 (7%)

40 (2%)

130 (7.7%)

115 (14%)

59 (19%)

<.001

Charlson comorbidity index >2

743 (16%)

65 (3%)

254 (15%)

282 (35%)

142 (46%)

<.001

Haematology and clinical chemistry

Haemoglobin, g/L

132 [118–145]

139 [127–150]

129 [116–143]

124 [110–136]

119 [106–131]

<.001

Estimated glomerular filtration rate, mL/min¶

70 [49–84]

77 [65–89]

68 [47–82]

53 [36–72]

48 [32–70]

<.001

Peak high sensitivity troponin I, ng/L (log)

NSTEMI

7.02 [5.24–8.63]

7.10 [5.27–8.66]

7.06 [5.32–8.67]

6.92 [5.23–8.61]

6.35 [4.66–8.18]

.02

STEMI

9.86 [8.22–10.82]

9.96 [8.35–10.82]

9.85 [8.18–10.82]

9.45 [7.94–10.82]

9.71 [7.98–10.82]

.08

Clinical diagnosis

NSTEMI

3262 (70%)

1075 (58%)

1264 (74%)

656 (82%)

267 (87%)

<.001

STEMI

1408 (30%)

790 (42%)

435 (26%)

142 (18%)

41 (13%)

Primary treating speciality

Cardiology

3146 (67%)

1586 (85%)

1097 (65%)

364 (46%)

99 (32%)

<.001

Medical therapy*

Aspirin

2587 (65%)

1292 (76%)

837 (59%)

340 (54%)

118 (52%)

<.001

P2Y12 inhibitor

3020 (75%)

1411 (83%)

1044 (73%)

420 (66%)

145 (63%)

<.001

Dual antiplatelet therapy†

2318 (58%)

1208 (71%)

736 (52%)

281 (44%)

93 (41%)

<.001

Anticoagulation‡

340 (9%)

90 (5.3%)

136 (9.5%)

83 (13%)

31 (14%)

<.001

ACE inhibitor or ARB

2067 (52%)

1061 (63%)

695 (49%)

248 (39%)

63 (28%)

<.001

Beta-blocker

2065 (52%)

1013 (60%)

677 (47%)

294 (47%)

81 (35%)

<.001

Lipid lowering therapy

2544 (64%)

1305 (77%)

837 (59%)

303 (48%)

99 (43%)

<.001

Revascularisation

Coronary angiography

2654 (57%)

1452 (78%)

881 (52%)

265 (33%)

56 (18%)

<.001

Percutaneous coronary intervention

1993 (43%)

1138 (61%)

622 (37%)

195 (24%)

38 (12%)

<.001

Coronary artery bypass grafting

151 (3%)

86 (5%)

46 (3%)

15 (2%)

<.001

Table 1

Open in new tab

Baseline characteristics and patient management

	Overall	electronic Frailty Index Category
	Overall	Fit	Mild	Moderate	Severe	P-value
N	4670	1865	1699	798	308
Patient demographics
Age (years)	77 [71–84]	72 [68–78]	79 [72–85]	81 [75–86]	82 [78–88]	<.001
Female	2014 (43%)	645 (35%)	784 (46%)	406 (51%)	179 (58%)	<.001
White	3865 (83%)	1419 (76%)	1449 (85%)	707 (89%)	290 (94%)	<.001
Deprivation (SIMD 1^st quintile)	648 (14%)	204 (11%)	235 (14%)	148 (19%)	61 (20%)	<.001
Chest pain as presenting symptom	3680 (82%)	1567 (87%)	1326 (81%)	568 (74%)	219 (73%)	<.001
Past medical history
Ischaemic heart disease	1989 (43%)	418 (22%)	805 (47%)	522 (65%)	244 (79%)	<.001
Myocardial infarction	1061 (23%)	213 (11%)	434 (26%)	287 (36%)	127 (41%)	<.001
Heart failure	772 (17%)	68 (3.6%)	274 (16%)	288 (36%)	142 (46%)	<.001
Cerebrovascular disease	838 (18%)	98 (5.3%)	323 (19%)	277 (35%)	140 (45%)	<.001
Peripheral vascular disease	558 (12%)	73 (3.9%)	227 (13%)	173 (22%)	85 (28%)	<.001
Diabetes mellitus	1139 (24%)	206 (11%)	446 (26%)	325 (41%)	162 (53%)	<.001
Chronic kidney disease	1249 (27%)	286 (15%)	494 (29%)	331 (41%)	138 (45%)	<.001
Hypertension	2964 (63%)	930 (50%)	1029 (61%)	497 (62%)	187 (61%)	<.001
Dementia	344 (7%)	40 (2%)	130 (7.7%)	115 (14%)	59 (19%)	<.001
Charlson comorbidity index >2	743 (16%)	65 (3%)	254 (15%)	282 (35%)	142 (46%)	<.001
Haematology and clinical chemistry
Haemoglobin, g/L	132 [118–145]	139 [127–150]	129 [116–143]	124 [110–136]	119 [106–131]	<.001
Estimated glomerular filtration rate, mL/min¶	70 [49–84]	77 [65–89]	68 [47–82]	53 [36–72]	48 [32–70]	<.001
Peak high sensitivity troponin I, ng/L (log)
NSTEMI	7.02 [5.24–8.63]	7.10 [5.27–8.66]	7.06 [5.32–8.67]	6.92 [5.23–8.61]	6.35 [4.66–8.18]	.02
STEMI	9.86 [8.22–10.82]	9.96 [8.35–10.82]	9.85 [8.18–10.82]	9.45 [7.94–10.82]	9.71 [7.98–10.82]	.08
Clinical diagnosis
NSTEMI	3262 (70%)	1075 (58%)	1264 (74%)	656 (82%)	267 (87%)	<.001
STEMI	1408 (30%)	790 (42%)	435 (26%)	142 (18%)	41 (13%)
Primary treating speciality
Cardiology	3146 (67%)	1586 (85%)	1097 (65%)	364 (46%)	99 (32%)	<.001
Medical therapy*
Aspirin	2587 (65%)	1292 (76%)	837 (59%)	340 (54%)	118 (52%)	<.001
P2Y12 inhibitor	3020 (75%)	1411 (83%)	1044 (73%)	420 (66%)	145 (63%)	<.001
Dual antiplatelet therapy†	2318 (58%)	1208 (71%)	736 (52%)	281 (44%)	93 (41%)	<.001
Anticoagulation‡	340 (9%)	90 (5.3%)	136 (9.5%)	83 (13%)	31 (14%)	<.001
ACE inhibitor or ARB	2067 (52%)	1061 (63%)	695 (49%)	248 (39%)	63 (28%)	<.001
Beta-blocker	2065 (52%)	1013 (60%)	677 (47%)	294 (47%)	81 (35%)	<.001
Lipid lowering therapy	2544 (64%)	1305 (77%)	837 (59%)	303 (48%)	99 (43%)	<.001
Revascularisation
Coronary angiography	2654 (57%)	1452 (78%)	881 (52%)	265 (33%)	56 (18%)	<.001
Percutaneous coronary intervention	1993 (43%)	1138 (61%)	622 (37%)	195 (24%)	38 (12%)	<.001
Coronary artery bypass grafting	151 (3%)	86 (5%)	46 (3%)	15 (2%)	<5	<.001

	Overall	electronic Frailty Index Category
	Overall	Fit	Mild	Moderate	Severe	P-value
N	4670	1865	1699	798	308
Patient demographics
Age (years)	77 [71–84]	72 [68–78]	79 [72–85]	81 [75–86]	82 [78–88]	<.001
Female	2014 (43%)	645 (35%)	784 (46%)	406 (51%)	179 (58%)	<.001
White	3865 (83%)	1419 (76%)	1449 (85%)	707 (89%)	290 (94%)	<.001
Deprivation (SIMD 1^st quintile)	648 (14%)	204 (11%)	235 (14%)	148 (19%)	61 (20%)	<.001
Chest pain as presenting symptom	3680 (82%)	1567 (87%)	1326 (81%)	568 (74%)	219 (73%)	<.001
Past medical history
Ischaemic heart disease	1989 (43%)	418 (22%)	805 (47%)	522 (65%)	244 (79%)	<.001
Myocardial infarction	1061 (23%)	213 (11%)	434 (26%)	287 (36%)	127 (41%)	<.001
Heart failure	772 (17%)	68 (3.6%)	274 (16%)	288 (36%)	142 (46%)	<.001
Cerebrovascular disease	838 (18%)	98 (5.3%)	323 (19%)	277 (35%)	140 (45%)	<.001
Peripheral vascular disease	558 (12%)	73 (3.9%)	227 (13%)	173 (22%)	85 (28%)	<.001
Diabetes mellitus	1139 (24%)	206 (11%)	446 (26%)	325 (41%)	162 (53%)	<.001
Chronic kidney disease	1249 (27%)	286 (15%)	494 (29%)	331 (41%)	138 (45%)	<.001
Hypertension	2964 (63%)	930 (50%)	1029 (61%)	497 (62%)	187 (61%)	<.001
Dementia	344 (7%)	40 (2%)	130 (7.7%)	115 (14%)	59 (19%)	<.001
Charlson comorbidity index >2	743 (16%)	65 (3%)	254 (15%)	282 (35%)	142 (46%)	<.001
Haematology and clinical chemistry
Haemoglobin, g/L	132 [118–145]	139 [127–150]	129 [116–143]	124 [110–136]	119 [106–131]	<.001
Estimated glomerular filtration rate, mL/min¶	70 [49–84]	77 [65–89]	68 [47–82]	53 [36–72]	48 [32–70]	<.001
Peak high sensitivity troponin I, ng/L (log)
NSTEMI	7.02 [5.24–8.63]	7.10 [5.27–8.66]	7.06 [5.32–8.67]	6.92 [5.23–8.61]	6.35 [4.66–8.18]	.02
STEMI	9.86 [8.22–10.82]	9.96 [8.35–10.82]	9.85 [8.18–10.82]	9.45 [7.94–10.82]	9.71 [7.98–10.82]	.08
Clinical diagnosis
NSTEMI	3262 (70%)	1075 (58%)	1264 (74%)	656 (82%)	267 (87%)	<.001
STEMI	1408 (30%)	790 (42%)	435 (26%)	142 (18%)	41 (13%)
Primary treating speciality
Cardiology	3146 (67%)	1586 (85%)	1097 (65%)	364 (46%)	99 (32%)	<.001
Medical therapy*
Aspirin	2587 (65%)	1292 (76%)	837 (59%)	340 (54%)	118 (52%)	<.001
P2Y12 inhibitor	3020 (75%)	1411 (83%)	1044 (73%)	420 (66%)	145 (63%)	<.001
Dual antiplatelet therapy†	2318 (58%)	1208 (71%)	736 (52%)	281 (44%)	93 (41%)	<.001
Anticoagulation‡	340 (9%)	90 (5.3%)	136 (9.5%)	83 (13%)	31 (14%)	<.001
ACE inhibitor or ARB	2067 (52%)	1061 (63%)	695 (49%)	248 (39%)	63 (28%)	<.001
Beta-blocker	2065 (52%)	1013 (60%)	677 (47%)	294 (47%)	81 (35%)	<.001
Lipid lowering therapy	2544 (64%)	1305 (77%)	837 (59%)	303 (48%)	99 (43%)	<.001
Revascularisation
Coronary angiography	2654 (57%)	1452 (78%)	881 (52%)	265 (33%)	56 (18%)	<.001
Percutaneous coronary intervention	1993 (43%)	1138 (61%)	622 (37%)	195 (24%)	38 (12%)	<.001
Coronary artery bypass grafting	151 (3%)	86 (5%)	46 (3%)	15 (2%)	<5	<.001

Presented as number (%), mean (±SD) or median [25th percentile, 75th percentile].

Abbreviations: SIMD = Scottish Index of Multiple Deprivation, CCI = Charlson comorbidity index, ACE = Angiotensin-converting enzyme; ARB = Angiotensin receptor blocker; NSTEMI = non-ST elevation myocardial infarction; STEMI = ST-elevation myocardial infarction.

^¶Value missing in 1469 patients.

^*Restricted to those alive at 30-days post-discharge (overall = 4074; fit = 1707; mild = 1465; moderate = 660; severe = 242).

^†Two medications from aspirin, clopidogrel, prasugrel and ticagrelor.

^‡Includes warfarin or novel anticoagulants.

This Feature Is Available To Subscribers Only